Lumoxiti Interactions
There are 72 drugs known to interact with Lumoxiti (moxetumomab pasudotox), along with 2 disease interactions. Of the total drug interactions, 32 are major, and 40 are moderate.
- View all 72 medications that may interact with Lumoxiti
- View Lumoxiti disease interactions (2)
Most frequently checked interactions
View interaction reports for Lumoxiti (moxetumomab pasudotox) and the medicines listed below.
- Afinitor Disperz (everolimus)
- Cuprimine (penicillamine)
- Depo Provera (medroxyprogesterone)
- enalapril
- estradiol
- Fioricet with Codeine (acetaminophen / butalbital / caffeine / codeine)
- Gammaplex (immune globulin intravenous)
- Gleevec (imatinib)
- Intron A (interferon alfa-2b)
- Jynarque (tolvaptan)
- Nipent (pentostatin)
- norethindrone
- Norplant System (levonorgestrel)
- Oriahnn (elagolix / estradiol / norethindrone)
- Orilissa (elagolix)
- Recombinate (antihemophilic factor)
- ribavirin
- Seasonique (ethinyl estradiol / levonorgestrel)
- Symdeko (ivacaftor / tezacaftor)
- Synagis (palivizumab)
Lumoxiti disease interactions
There are 2 disease interactions with Lumoxiti (moxetumomab pasudotox) which include:
Report options
QR code containing a link to this page
More about Lumoxiti (moxetumomab pasudotox)
- Lumoxiti consumer information
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.